SGLT2 inhibitors in heart failure — Research & Evidence

Q: What does the research say about SGLT2 inhibitors in heart failure?

The scientific consensus on SGLT2 inhibitors in heart failure is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for SGLT2 inhibitors in heart failure?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about SGLT2 inhibitors in heart failure?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Evidence brief: SGLT2 inhibitors in heart failure

SGLT2 inhibitors in heart failure (also known as SGLT2i HF, empagliflozin heart failure, dapagliflozin heart failure). SGLT2i trials and outcomes in HF patients

As of 2026-06-25, the scientific consensus on SGLT2 inhibitors in heart failure is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on SGLT2 inhibitors in heart failure. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a307b42209bc31dca333.

Deterministic synthesis from Synapse's enriched corpus — 215 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for SGLT2 inhibitors in heart failure?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest SGLT2 inhibitors in heart failure research

Explore every SGLT2 inhibitors in heart failure paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search SGLT2 inhibitors in heart failure papers